BioPharma Credit PLC (BOPCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioPharma Credit PLC (BOPCF) trades at $0.96 with AI Score 45/100 (Grade C). BioPharma Credit PLC is an investment trust that specializes in providing debt financing to the life sciences industry. Market cap: $1.09B, Sector: Financial services.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BOPCF: BOPCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BOPCF against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BOPCF: the 1 perspectives are evenly split.
How is this calculated? →BioPharma Credit PLC (BOPCF) Financial Services Profile
BioPharma Credit PLC is a UK-based investment trust focused on secured debt investments in the life sciences sector, leveraging royalties and cash flows from approved products. With a high dividend yield and a relatively low beta, the company offers a unique investment profile within the asset management industry.
What Is the Investment Thesis for BOPCF?
BioPharma Credit PLC presents a compelling investment case based on its unique focus on secured debt within the life sciences sector. The company's strategy of securing investments with royalties and cash flows from approved products provides a degree of stability and predictability. With a current dividend yield of 12.49% and a P/E ratio of 8.74, the company offers an attractive income stream. The company's low beta of 0.21 suggests a lower volatility compared to the broader market. Growth catalysts include the increasing demand for specialized financing solutions within the life sciences industry and the company's ability to deploy capital effectively. However, potential risks include changes in interest rates and the performance of the underlying assets securing the debt. Monitoring the company's ability to maintain its dividend yield and manage its portfolio risk is crucial.
Based on FMP financials and quantitative analysis
BOPCF Key Highlights
- Market capitalization of $1.09B, indicating a significant presence in the investment trust market.
- P/E ratio of 8.74, suggesting a potentially undervalued stock compared to its earnings.
- Profit margin of 100.5%, reflecting efficient operations and strong profitability.
- Gross margin of 115.4%, indicating a substantial difference between revenue and the cost of goods sold.
- Dividend yield of 12.49%, offering a high income stream for investors.
Who Are BOPCF's Competitors?
BOPCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BOMXF Bolsa Mexicana de Valores, S.A.B. de C.V. | $2.06 | +0.00% | $1.14B | 50 |
| CNECF Centuria Capital Group | $1.03 | +0.00% | $996.06M | 41 |
| GCAAF Guardian Capital Group Limited | $49.40 | -0.22% | $1.21B | 58 |
| IHPGF IntegraFin Holdings plc | $2.75 | +0.00% | $908.53M | 52 |
| IOOFF Insignia Financial Ltd. | $1.30 | +0.00% | $871.94M | 49 |
| NXDT NexPoint Diversified Real Estate Trust | $5.36 | +1.32% | $277.24M | 73 |
| GENB Generate Biomedicines, Inc. | $17.41 | +5.52% | $2.23B | 72 |
| SII Sprott Inc. | $114.98 | +2.00% | $2.96B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BOPCF's Key Strengths?
- Specialized focus on life sciences debt financing.
- Secured investments with royalties and cash flows.
- High dividend yield.
- Low beta, indicating lower volatility.
What Are BOPCF's Weaknesses?
- Dependence on the performance of underlying assets.
- Sensitivity to interest rate changes.
- Limited diversification within the life sciences sector.
- Small number of employees.
What Could Drive BOPCF Stock Higher?
- Potential acquisitions of smaller life science investment firms to expand market reach.
- Increasing demand for specialized financing solutions within the life sciences industry.
- Strategic partnerships with pharmaceutical companies to provide financing for drug development.
- Expansion into new geographic markets with growing life sciences sectors.
What Are the Key Risks for BOPCF?
- Changes in interest rates affecting the profitability of debt investments.
- Failure of key pharmaceutical products securing investments.
- Dependence on the performance of underlying assets and royalty streams.
- Regulatory changes impacting the life sciences industry.
- Economic downturn affecting the ability of borrowers to repay debt.
What Are the Growth Opportunities for BOPCF?
- Expansion into new geographic markets: BioPharma Credit PLC can expand its operations into new geographic markets, such as Asia and Latin America, where the demand for life sciences financing is growing rapidly. This expansion could increase the company's revenue and profitability. The global biotechnology market is projected to reach $3.88 trillion by 2030, presenting a significant opportunity for growth.
- Increased investment in innovative therapies: The company can increase its investment in innovative therapies, such as gene therapy and personalized medicine, which are expected to drive growth in the life sciences industry. This could lead to higher returns on investment and increased market share. The market for gene therapy is projected to reach $36.9 billion by 2030.
- Strategic partnerships with pharmaceutical companies: BioPharma Credit PLC can form strategic partnerships with pharmaceutical companies to provide financing for the development and commercialization of new drugs. This could provide the company with access to a wider range of investment opportunities and increase its brand recognition. The pharmaceutical industry is projected to reach $1.7 trillion by 2027.
- Development of new financial products: The company can develop new financial products, such as royalty-backed loans and revenue-sharing agreements, to meet the evolving needs of the life sciences industry. This could attract new customers and increase the company's revenue streams. The market for royalty-backed financing is estimated to be worth billions of dollars.
- Acquisition of smaller investment firms: BioPharma Credit PLC can acquire smaller investment firms that specialize in life sciences financing. This could expand the company's expertise and market reach. The asset management industry is highly fragmented, presenting opportunities for consolidation.
What Opportunities Does BOPCF Have?
- Expansion into new geographic markets.
- Increased investment in innovative therapies.
- Strategic partnerships with pharmaceutical companies.
- Development of new financial products.
What Threats Does BOPCF Face?
- Changes in regulations affecting the life sciences industry.
- Increased competition from other investment firms.
- Economic downturn affecting the ability of borrowers to repay debt.
- Failure of key pharmaceutical products securing investments.
What Are BOPCF's Competitive Advantages?
- Specialized expertise in life sciences financing.
- Focus on royalty-backed debt, providing a stable revenue stream.
- Established relationships with pharmaceutical companies.
- High barrier to entry due to the complexity of the life sciences industry.
What Does BOPCF Do?
BioPharma Credit PLC, established in 2016 and headquartered in Exeter, United Kingdom, operates as a specialized investment trust. The company's core business revolves around providing debt financing to companies within the life sciences industry. Unlike traditional lenders, BioPharma Credit PLC focuses on securing its investments with royalties and other predictable cash flows generated from the sales of approved life science products. This strategy allows them to tap into a relatively stable revenue stream, mitigating some of the risks associated with early-stage drug development. The company's investment portfolio consists primarily of interest-bearing debt assets. These assets are carefully selected and structured to ensure a high degree of security and predictable returns. By focusing on approved products with established market presence, BioPharma Credit PLC aims to generate consistent income for its shareholders through dividend distributions. The company's unique approach to life sciences financing has positioned it as a niche player within the broader asset management landscape. BioPharma Credit PLC does not directly engage in the development or commercialization of pharmaceutical products. Instead, it acts as a financial partner, providing capital to companies that already have approved products on the market. This allows the company to avoid the high costs and risks associated with drug development, while still benefiting from the growth and profitability of the life sciences industry.
What Products and Services Does BOPCF Offer?
- Provides debt financing to life sciences companies.
- Secures investments with royalties and cash flows from approved products.
- Manages a portfolio of interest-bearing debt assets.
- Generates income through interest payments and royalty streams.
- Distributes dividends to shareholders.
- Focuses on approved pharmaceutical products with established market presence.
How Does BOPCF Make Money?
- Invests in debt secured by royalties or other cash flows from approved life sciences products.
- Generates revenue through interest payments and royalty streams.
- Distributes profits to shareholders through dividends.
- Manages risk by focusing on approved products with established market presence.
What Industry Does BOPCF Operate In?
BioPharma Credit PLC operates within the asset management industry, specifically focusing on debt financing for the life sciences sector. The market for life sciences financing is driven by the increasing costs of drug development and the need for specialized funding solutions. The competitive landscape includes other asset management firms and investment trusts, such as BOMXF (BB Biotech AG), CNECF (HBM Healthcare Investments AG), GCAAF ( Bellevue Group AG), IHPGF (International Biotechnology Trust PLC), and IOOFF (Worldwide Healthcare Trust PLC), but BioPharma Credit PLC differentiates itself through its focus on royalty-backed debt.
Who Are BOPCF's Key Customers?
- Life sciences companies seeking debt financing.
- Pharmaceutical companies requiring capital for drug development and commercialization.
- Investors seeking income through dividend distributions.
- Institutions looking for exposure to the life sciences sector.
BOPCF Valuation & Market Position
With a $1.09B market cap, BioPharma Credit PLC sits in the small-cap segment of the market. Relative to its peer group, BOPCF's quantitative score of 45/100 is roughly in line with the peer average of 50/100.
ROE 11%Key Financial Metrics
Return on equity for BioPharma Credit PLC stands at 11.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.1%, showing how much profit it generates from its asset base. BOPCF trades at a trailing price-to-earnings ratio of 8.29, below the Financial Services sector average of ~18x. Its free cash flow yield is 8.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 12.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
BioPharma Credit PLC's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 38.99 places it in the safe zone, indicating low near-term bankruptcy risk.
BOPCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating potential growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative pipeline and strategic partnerships.
- Market perception has improved as recent announcements reinforce BioPharma's role in the growing biopharmaceutical sector.
- Investors are optimistic about regulatory approvals that could unlock new revenue streams for BioPharma.
Bear Case
- Concerns about the overall economic environment may dampen investor enthusiasm for biopharma investments.
- Some community members express skepticism regarding the sustainability of recent gains, citing potential overvaluation.
- Recent market developments have raised questions about competitive pressures in the biopharma space, leading to cautious sentiment.
- Insider selling activity has raised red flags for some investors, suggesting a lack of confidence from certain stakeholders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BOPCF Latest News
-
Science Group And 2 Other Undiscovered Gems in the United Kingdom
Yahoo! Finance: BOPCF News · Jun 1, 2026
-
Uncovering Anglo Asian Mining And 2 Promising Small Caps In The UK Market
Yahoo! Finance: BOPCF News · May 27, 2026
-
Undiscovered Gems in the United Kingdom for May 2026
Yahoo! Finance: BOPCF News · May 25, 2026
-
CAB Payments Holdings And 2 Other Undiscovered Gems In The United Kingdom
Yahoo! Finance: BOPCF News · May 22, 2026
BOPCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BOPCF.
Price Targets
Wall Street price target analysis for BOPCF.
BOPCF MoonshotScore
What does this score mean?
The MoonshotScore rates BOPCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Science Group And 2 Other Undiscovered Gems in the United Kingdom
Uncovering Anglo Asian Mining And 2 Promising Small Caps In The UK Market
Undiscovered Gems in the United Kingdom for May 2026
CAB Payments Holdings And 2 Other Undiscovered Gems In The United Kingdom
Leadership: Pedro Gonzalez de Cosio
CEO
Pedro Gonzalez de Cosio serves as the CEO of BioPharma Credit PLC, bringing extensive experience in finance and investment management. His career spans various roles in the financial sector, with a focus on debt financing and investment strategies. He has a strong background in structuring and managing complex financial transactions, particularly within the healthcare and life sciences industries. His expertise includes portfolio management, risk assessment, and capital allocation.
Track Record: Under Pedro Gonzalez de Cosio's leadership, BioPharma Credit PLC has focused on expanding its portfolio of royalty-backed debt investments. He has overseen strategic decisions to diversify the company's investments and enhance its risk management framework. Key milestones include maintaining a high dividend yield for shareholders and navigating the complexities of the life sciences financing market.
BOPCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioPharma Credit PLC may not meet the listing requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier typically includes companies with limited trading volume and higher associated risks compared to those on more regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Reduced regulatory oversight compared to major exchanges.
- Potential for fraud or manipulation due to less stringent listing requirements.
- Higher risk of illiquidity.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC securities.
- Monitor trading volume and price movements.
- Consult with a qualified financial advisor.
- Company's history of dividend payments.
- Focus on secured debt investments.
- Presence of a dedicated management team.
- Audited financial statements (if available).
- Publicly available information on the company's website.
BOPCF Financial Services Stock FAQ
What does BioPharma Credit PLC do?
BioPharma Credit PLC is an investment trust that specializes in providing debt financing to companies within the life sciences industry. The company focuses on securing its investments with royalties and other cash flows generated from approved pharmaceutical products. This approach allows BioPharma Credit PLC to generate consistent income through interest payments and royalty streams, which are then distributed to shareholders through dividends. The company's business model provides a unique way to invest in the life sciences sector without directly engaging in drug development.
What are the main risks for BOPCF?
The main risks for BioPharma Credit PLC include changes in interest rates, which could affect the profitability of its debt investments. Another significant risk is the potential failure of key pharmaceutical products securing its investments, which could impact royalty streams. Additionally, regulatory changes within the life sciences industry and economic downturns affecting the ability of borrowers to repay debt pose ongoing threats. Investors should also consider the company's limited diversification within the life sciences sector and its dependence on a relatively small number of employees.
What are the key factors to evaluate for BOPCF?
BioPharma Credit PLC (BOPCF) holds an AI score of 45/100 (low). Not financial advice.
How frequently does BOPCF data refresh on this page?
BOPCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BOPCF's recent stock price performance?
BioPharma Credit PLC (BOPCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on life sciences debt financing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BOPCF overvalued or undervalued right now?
Valuing BioPharma Credit PLC (BOPCF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BOPCF?
Before investing in BioPharma Credit PLC (BOPCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BOPCF to a portfolio?
Key strength of BioPharma Credit PLC (BOPCF): Specialized focus on life sciences debt financing. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than major exchange data.
- AI analysis is pending for BOPCF.